Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients

Molecular Vision

Volumn 15, Issue , 2009, Pages 1638-1648

  Bai, Shumei ^a   Liu, Shilian ^a,e   Guo, Xuxiao ^b   Qin, Zhaoyu ^c,f   Wang, Banqin ^a   Li, Xiaohong ^a   Qin, Yanjiang ^d   Liu, Yi Hsin ^e  

^a Shandong Provincial Key Laboratory of Mental Disorders   (China)

^b AFFILIATED HOSPITAL OF SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SHANDONG UNIVERSITY   (China)

^d SHANDONG UNIVERSITY   (China)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ISOPROTEIN; PROTEOME;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MYELOOPTIC NEUROPATHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; BLOTTING, WESTERN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HAPTOGLOBINS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NEUROMYELITIS OPTICA; PEPTIDE MAPPING; PEPTIDES; PROTEIN ISOFORMS; PROTEOME; REPRODUCIBILITY OF RESULTS; VITAMIN D-BINDING PROTEIN;

EID: 69249229818     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Matiello M, Jacob A, Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Opin Neurol 2007; 20:255-60.
2. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, Holander C, Bichara RP, Thuler LC. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol 2008; 126:12-6.
3. Bergamaschi R, Ghezzi A. Devic's neuromyelitis optica: clinical features and prognostic factors. Neurol Sci 2004; 25:S364-7.
4. Feingold RM. Neuromyelitis optica. J Insur Med 2008; 40:136-40.
5. Saiz A, Zuliani L, Blanco Y, Tavolato B, Giometto B, Graus F, Spanish-Italian NMO Study Group. Revised diagnostic criteria for neuromyelitis optica (NMO). Application in a series of suspected patients. J Neurol 2007; 254:1233-7.
6. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364:2106-12.
7. Argyriou AA, Makris N. Neuromyelitis optica: a distinct demyelinating disease of the central nervous system. Acta Neurol Scand 2008; 118:209-17.
8. Lana-Peixoto MA. Devic's neuromyelitis optica: a critical review. Arq Neuropsiquiatr 2008; 66:120-38.
9. Yuan X, Desiderio DM. Proteomics analysis of phosphotyrosylproteins in human lumbar cerebrospinal fluid. J Proteome Res 2003; 2:476-87.
10. Yuan X, Desiderio DM. Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 815:179-89.
11. Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J, Van Meir EG, Ritchie JC, Brat DJ. Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 2006; 6:6277-87.
12. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53:1107-14.
13. Liu XD, Zeng BF, Xu JG, Zhu HB, Xia QC. Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. Proteomics 2006; 6:1019-28.
14. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
15. Ciborowski P, Enose Y, Mack A, Fladseth M, Gendelman HE. Diminished matrix metalloproteinase 9 secretion in human immunodeficiency virus-infected mononuclear phagocytes: modulation of innate immunity and implications for neurological disease. J Neuroimmunol 2004; 157:11-6.
16. Miyazawa I, Nakashima I, Petzold A, Fujihara K, Sato S, Itoyama Y. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 2007; 68:865-7.
17. Wingerchuk DM, Lucchinetti CF. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis. Curr Opin Neurol 2007; 20:343-50.
18. Lim ET, Grant D, Pashenkov M, Keir G, Thompson EJ, Söderström M, Giovannoni G. Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Mult Scler 2004; 10:261-5.
19. Jin T, Hu LS, Chang M, Wu J, Winblad B, Zhu J. Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Eur J Neurol 2007; 14:563-8.
20. Yang YR, Liu SL, Qin ZY, Liu FJ, Qin YJ, Bai SM, Chen ZY. Comparative proteomics analysis of cerebrospinal fluid of patients with Guillain-Barré syndrome. Cell Mol Neurobiol 2008; 28:737-44.
21. Lehmensiek V, Süssmuth SD, Tauscher G, Brettschneider J, Felk S, Gillardon F, Tumani H. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007; 13:840-50.
22. Hammack BN, Fung KYC, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP, Gilden DH. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004; 10:245-60.
23. Correale J, Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004; 63:2363-70.
24. Leonardi A, Arata L, Farinelli M, Cocito L, Schenone A, Tabaton M, Mancardi GL. Cerebrospinal fluid and neuropathological study in Devic's syndrome. Evidence of intrathecal immune activation. J Neurol Sci 1987; 82:281-90.
25. Tseng CF, Lin CC, Huang HY, Liu HC, Mao SJ. Antioxidant role of human haptoglobin. Proteomics 2004; 4:2221-8.
26. Wagner L, Gessl A, Baumgartner Parzer S, Base W, Waldhausl W, Pasternack MS. Haptoglobin phenotyping by newly developed monoclonal antibodies. Demonstration of haptoglobin uptake into peripheral blood neutrophils and monocytes. J Immunol 1996; 156:1989-96.
27. Berkova N, Gilbert C, Goupil S, Yan J, Korobko V, Naccache PH. TNF-induced haptoglobin release from human neutrophils: pivotal role of the TNF p55 receptor. J Immunol 1999; 162:6226-32.
28. Halaby DM, Mornon JP. The immunoglobulin superfamily: an insight on its tissular, species, and functional diversity. J Mol Evol 1998; 46:389-400.
29. Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NF kappa B, STAT and AP1 transcription factor families. Histol Histopathol 2001; 16:595-601.
30. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005; 24:970-9.
31. Albrecht U, Yang X, Asselta R, Keitel V, Tenchini ML, Ludwig S, Heinrich PC, Häussinger D, Schaper F, Bode JG. Activation of NF-kappaB by IL-1beta blocks IL-6-induced sustained STAT3 activation and STAT3-dependent gene expression of the human gamma-fibrinogen gene. Cell Signal 2007; 19:1866-78.
32. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936:11-30.
33. Conti A, Sanchez-Ruiz Y, Bachi A, Beretta L, Grandi E, Beltramo M, Alessio M. Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. J Neurotrauma 2004; 21:854-63.
34. McLeod JF, Cooke NE. The vitamin D-binding protein, α-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues. J Biol Chem 1989; 264:21760-9.
35. Van Baelen H, Bouillon R, De Moor P. Vitamin D-binding protein (Gcglobulin) binds actin. J Biol Chem 1980; 255:2270-2.
36. Meier U, Gressner O, Lammert F, Gressner AM. Gc-globulin: roles in response to injury. Clin Chem 2006; 52:1247-53.
37. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194:7-17.
38. Qin Z, Qin YJ, Liu SL. Alteration of DBP Levels in CSF of Patients with MS by Proteomics Analysis. Cell Mol Neurobiol 2009; 29:203-10.
39. Liz MA, Gomes CM, Saraiva MJ, Sousa MM. ApoA-I cleaved by transthyretin has reduced ability to promote cholesterol efflux and increased amyloidogenicity. J Lipid Res 2007; 48:2385-95.
40. Ranganathan S, Williams E, Ganchev P, Gopalakrishnan V, Lacomis D, Urbinelli L, Newhall K, Cudkowicz ME, Brown RH, Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J Neurochem 2005; 95:1461-71.
41. Tu GF, De Jong F, Apostolopoulos J, Nagashima M, Fidge N, Schreiber G, Howlett G. Effect of acute inflammation on rat apolipoprotein mRNA levels. Inflammation 1987; 11:241-51.
42. Langner CA, Birkenmeier EH, Roth KA, Bronson RT, Gordon JI. Characterization of the peripheral neuropathy in neonatal and adult mice that are homozygous for the fatty liver dystrophy (fld) mutation. J Biol Chem 1991; 266:11955-64.
43. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J, Nicoletti A. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001; 104:197-202.
44. Gaillard O, Gervais A, Meillet D, Plassart E, Fontaine B, Lyon-Caen O, Delattre J, Schuller E. Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation. J Neurol Sci 1998; 158:180-6.
45. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001; 66:510-6.
46. Iizuka H, Awata T, Osaki M, Neda T, Kurihara S, Inoue K, Inukai K, Kabasawa S, Mori K, Yoneya S, Katayama S. Promoter polymorphisms of the pigment epithelium-derived factor gene are associated with diabetic retinopathy. Biochem Biophys Res Commun 2007; 361:421-6.
47. Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res 2004; 23:561-77.